The therapeutic effect comes ...

The therapeutic effect occurs within 3-6 weeks. During antidepressant therapy Pirazidol appointed into tablets containing 25 or 50 mg. The initial daily dose is 50-100 mg, increasing the dose gradually implemented under the supervision of clinical action and tolerability to 150-300 mg per day. For the treatment of mild to moderate depression degree is usually sufficient daily dose of 100-200 mg, more severe depressive states dose may be increased to 250-300 mg per day. The maximum daily dose is 400 mg. Judgement about the effectiveness of treatment Pirazidolom may be imposed after three to four weeks of treatment. In achieving positive results, treatment should be continued for 4-6 months as maintenance therapy to prevent relapse. Canceling the drug should be made after the gradual reduction of the dose for a month under the supervision of the mental state to avoid the development or worsening of withdrawal syndrome with vegetative symptoms (nausea, anorexia, headache, dizziness, chills). Toxicological studies showed the absence of potentially harmful toxic effects Pirazidola even with prolonged administration of doses higher than therapeutic. Not detected clinically significant mutagenic, carcinogenic and clastogenic (induction of chromosome aberrations) properties. Pirazidol included in the intermediate group of antidepressants with a wider, multivalent or a balanced spectrum of activity. Timoanalepticheskoe action Pirazidola quite pronounced, but concedes anafranilu; of the total (global) effectiveness of the drug is regarded as an antidepressant second rank [7]. Severity of challenging properties in Pirazidola less than that of imipramine and clomipramine, but more than that of fluoxetine and amitriptyline ludiomila. Anxiolytic effect Pirazidola surpasses that of fluoxetine. The strength of the drug antifobicheskogo inferior clomipramine, SSRIs, but superior amitriptyline ludiomil. Sedative and hypnotic properties less pronounced than that of tricyclic antidepressants, but is more noticeable than in the fluoxetine, flyuvoksamina. The main feature of the clinical effect Pirazidola lies in the fact that the drug as an antidepressant is characterized by tropism as a disturbing and retarded depression. Clinical aspects of Pirazidola to treat depression in the first 20 years after its development has been to diversify studied at a special studies in leading psychiatric centers in the country. The object of the study were mostly inpatients with endogenous depression. Fast enough positive experiences Pirazidola as an antidepressant and has spread to outpatient management of patients with superficial forms of depressive disorders in different age groups of patients. Range of indications for the drug significantly increased. In addition to endogenous depression, Pirazidol found to be effective in depression and other origins, in particular, for a variety of psychogenic-induced depression, depression in the organic diseases, as well as in depressive disorders in general somatic practice.